Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Keywords

Affiliated Institutions

• Dutch Cancer Society NL
• The Netherlands Cancer Institute NL
• Beverly Hills Cancer Center US
• Temple University US
• University of California, Los Angeles US
• Universitätsklinikum Tübingen DE
• University of Zurich CH
• Université Paris-Sud FR
• Duke Cancer Institute
• Merck & Co., Inc., Rahway, NJ, USA (United States) US
• University of Pennsylvania US
• St. Luke's University Health Network US
• University of North Carolina at Chapel Hill US
• Seattle Cancer Care Alliance US
• Blacktown & Mount Druitt Hospital AU
• Melanoma Institute Australia AU
• Vanderbilt-Ingram Cancer Center
• Sheba Medical Center IL
• University of Arizona US
• University of Pittsburgh US
• University Medical Center of the Johannes Gutenberg University Mainz DE
• Institut Gustave Roussy FR
• Angeles Clinic and Research Institute US
• University of Colorado Denver US
• Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" IT
• Johannes Gutenberg University Mainz DE
• Dana-Farber Cancer Institute US
• Vanderbilt University US
• New York University US
• University of Arizona Cancer Center
• University of Washington US
• University of California, San Francisco US
• Memorial Sloan Kettering Cancer Center US
• Essen University Hospital DE

Related Publications